infectious diseases
Mupirocin
Introduction
 inhibits bacterial RNA and protein synthesis. It is available only as a 2% topical preparation, which is bactericidal against Staphylococcal Infections and beta-hemolytic Mupirocinis used for Impetigo and Ecthyma None Minor superficial secondarily infected skin lesions Eradication ofStaphylococcus aureusnasal carriage, although relapse rates may be high Chronic therapy leads tomupirocin-resistant staphylococci. Mupirocinis nontoxic but, when applied to denuded skin or mucous membranes, may cause itching and burning. 